Protea Biosciences Group Inc. (fka PRGBQ)

[Roland Rick Perry]

Studying this..

...as if this is the first day we ever looked at it.

8 million shares (after 50:1) equates to a $9.2 million market cap @ $1.15. Modest for any Company, most will agree, involved in cancer diagnostics.

Interesting side note. Steve Antoline a former director and the largest shareholder along with his wife Jamie, graciously donated $1 million to WVU for cancer research in August, which is walking distance from Protea's HQ's.

"..many great institutions and universities, including WVU, have come a long way with early detection methods, and in many cases, treatment that can help a cancer patient live a long and productive life. How great it would be if, with the help of research dollars, the cure for cancer was found at WVU." Steve Antoline.

https://wvutoday.wvu.edu/stories/2017/08/25/nicholas-county-couple-donates-1m-to-wvu-s-norma-mae-huggins-cancer-research-fund

Shareholder Roster (4/17)

https://www.otcmarkets.com/financialReportViewer?symbol=PRGBD&id=176960

"How great would it be if Protea's cancer detection technology jointly developed with Yale University, gets widely adopted and saves countless lives, by providing a quicker and more accurate prognostic/diagnostic melanoma cancer testing result and subsequent treatment decision?" Roland Perry :)

(In October 2015 scientists at Yale and Protea presented the results of their first clinical study at the 52nd Annual Meeting of the American Society of Dermatopathology (ASDP), held in San Francisco, CA. The sensitivity and specificity of the new method were shown to be 99%, and the test correctly classified all cases of malignant melanoma and benign melanocytic nevi. There are globally approximately three million skin biopsies annually to rule out the presence of melanoma; of these approximately 25% come back as “indeterminate” or “unknown”.)

https://www.europeanpharmaceuticalreview.com/article/40677/proteomic-mass-spectrometry-melanoma/

What we will be studying with great interest is the 'office level' experience of both the Physician and patient, after undergoing a biopsy which comes back as "don't know or not sure," if the patient actually has skin cancer or not.

Symbol goes back to PRGB November 13th.